High prevalence of late diagnosis of HIV in Mexico during the HAART era

Salud Publica de Mexico

Volumn 54, Issue 5, 2012, Pages 506-514

  Crabtree Ramírez, Brenda ^a   Caro Vega, Yanink ^a   Belaunzarán Zamudio, Francisco ^b   Sierra Madero, Juan ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Delayed diagnosis; HIV; Mexico; Risk factors

Indexed keywords

EID: 84867827846     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/S0036-36342012000500007     Document Type: Article

References (57)

1. Palíela FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus infection. New Engl J Med 1998;338(13):853-860.
2. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373(9672):1352-1363. Epub 2009 Apr. 8.
3. NA-ACCORD Investigators, Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360(18):1815-1826. Epub 2009 Apr. I.
4. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in the AIDS and death rates In the EuroSIDA study: an observational study. Lancet 2003;362(9377):22-29.
5. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363(3):257-265. PubMed PMID:20647201.
6. Mills E, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy, evidence from a large cohort in Uganda. AIDS 2011;25(6):851-855.
7. Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005;40(1):96-101.
8. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008;198(1):59-67.
9. Barry SM, Lloyd-Owen SJ, Madge SJ, Cozzi-Lepri A, Evans AJ, Phillips AN, et al. The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Med 2002;3(2):129-134.
10. Sabin C, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004;18(16):2145-2151.
11. Girardi E, Aloisi MS, Arici C, Pezzotti P, Serraino D, Balzano R, et al. for the ICoNA Behavioral Epidemiology Study Group. Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr 2004;36(4):951-959. PubMed PMID:15220702.
12. The UK Collaborative HIV Cohort (UK CHIC) Steering Committee UK, Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, et al. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010;24(5):723-727. PubMed PMID:20057312.
13. l3. Fisher M. Late diagnosis of HIV Infection: major consequences and missed opportunities. Curr Opin Infect Dis 2008;21:1-3.
14. World Health Organization. Approaches to rationing antiretroviral treatment ethical and equity implications. Bull World Health Org 2005;83(7):541-547.
15. Magis-Rodríguez C, Bravo E, Gayet C, Rivera P, De Luca M. El VIH y el SIDA en México al 2008, hallazgos, tendencias y reflexiones. México, D. F.: CENSIDA, 2008: p. 88 [Accessed 22 March 2011]. Available from: http://www.censida.salud.gob.mx/descargas/biblioteca/VIHSIDA-MEX2008.pdf
16. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. ART-LINC Collaboration of leDEA. Long-term Immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008;22(17):2291-2302.
17. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewieckl A, Cahn P, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009;51(5):615-623.
18. Bonjour M, Montagne M, Zambrano M, Molina G, Lippuner C, Wadskier FG, et al. Determinants of late disease-stage presentation at diagnosis of HIV infection in Venezuela: A case-case comparison. AIDS Res Ther 2008;5:6.
19. Centers for Disease Control and Prevention. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years. 2008; MMWR57(No. RR-10):1-16 [Accessed 22 March 2011]. Available from: http//www.cdc.gov/mmwr/PDF/rr/rr57IO.pdf
20. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 2009;21(3):284-293.
21. KerulyJ, Moore R. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007;45:I369-1374.
22. Borghl V, Girardi E, Bellelli S, Angeletti C, Mussini C, Porter K, et al. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr 2008;49:282-286.
23. Guy RJ, McDonald AM, Bartlett MJ, Murray JC, Giele CM, Davey TM, et al. Characteristics of HIV diagnoses in Australia, 1993-2006. Sexual Health 2008;5(2):91-96.
24. Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, Emenyonu NI, et al. Late-disease stage at presentation to an HIV Clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2009;52(2):280-289.
25. Kassa E, Rinke de Wit TF, Hailu E, Girma M, Messele T, Mariam HG et al. Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. AIDS 1999;13(3):381-389.
26. Malamba SS, Morgan D, Clayton T, Mayanja B, Okongo M, Whitworth J. The prognostic value of the World Health Organization staging system for HIV infection and disease in rural Uganda. AIDS 1999;13(18):2555-2561
27. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups, Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006:367(9513):817-824.
28. Louis C, Ivers LC, Smith F, Freedberg KA, Castro A. Late presentation for HIV care in central Haiti: factors limiting access to care. AIDS Care 2007;4:487-491.
29. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for Human Immunodeficiency Virus care in the United States and Canada. Clin Infect Dis 2010;50(11):1512-1520.
30. Bautista A S, Mane A, Bertozzi SM. Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment AIDS 2006;20(1):101-109.
31. Magis C, Hernández M. Epidemiología del SIDA en México. En: Cordova VJ, Ponce de L S, Valdespino JL 25 años de SIDA en México: logros, desaciertos y retos. 2a. edición. México: CENSIDA, 2009:101-117. [Accessed 22 March 2011]. Disponible en: http://www.censida.salud.gob. mx/descargas/SIDA25axos-26mar.pdf
32. Marazzi MC, Üotta G, Germano P, Guidotti G, Altan AD, Ceffa S, et al. Excessive early mortality in the first year of treatment in HIV type I-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 2008;24(4):555-560.
33. Ministerio de Salud. Recomendaciones para el tratamiento antirretroviral 2007. Argentina;2007. [Accessed 22 March 2011]. Available from: http://www.msal.gov. ar/sida/pdf/info-equipos-salud/recomendacionestratamiento- antirretroviral.pdf.
34. Ministerio de Salud. Guia clínica síndrome de la inmunodeficiencia adquirida VIH/SIDA. Santiago: Ministerio de Salud, 2005.
35. Ministerio de Salud. Guía nacional de atención integral de la persona viviendo con el VIH/SIDA. (PWIH/S). 2a. edición. Lima, 2006. [Accessed 22 March 2011]. Available from: http://www.care.org.pe/Websites/ FondoMundial/materiales/TB-VIH/VIH/VIH4/Gu%C3%ADa%20Nacional%20 Atenci%C3%B3n%20lnt.egral.pdf.
36. Ministerio de protección y fundación para la investigación y el desarrollo de la salud y la seguridad social. Guia para el manejo de VIH/SIDA basada en la evidencia. Bogotá, 2005 [Accessed 22 March 2011]. Available from: http://www.saludcolombia.com/actual/documentos/ GUIA%20 DE%20ATENCION%20VIH-SIDA%20version%20oficial.pdf
37. Ministerio del poder popular para la salud. Guía para el manejo del tratamiento antirretrovlral de las personas que viven con el VIH/SIDA en Venezuela Programa Nacional de SIDA/ITS 2008-2009. 3a. edición. Caracas, 2008. [Accessed 22 March 2011]. Available from: http://www.mpps.gob.ve/ Boletines/sida/Guia-TARV.pdf
38. Centro nacional para la prevención y el control de VIH/SIDA. Gula de manejo antirretroviral de las personas con VIH. 4a. edición. México: CENSIDA, 2009. [Accessed 22 March 2011]. Available from: http://www.censida.salud.gob.mx/descargas/biblioteca/guia-arv09.pdf.
39. Crabtree-Ramírez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortes C et al. 2011 Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS ONE 6(5):e20272. doi:10.1371/journal.pone.0020272
40. Centers for Disease Control and Prevention. Late versus early testing of HIV sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep 2003;32:581-586.
41. Castilla J, Sobrino P, de la Fuente L, Noguer I, Guerra L and Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2006;16:1945-1951.
42. Girardi E, Sabin C, Monforte AD. Late Diagnosis of HIV Infection: Epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007;46(Supp 1):S3-S8.
43. Programa de acción específico, 2007-2012 en respuesta al VIH/SIDA e ITS; Secretaría de Salud, Subsecretaría de Prevención y Promoción de la Salud. México, 2008:27-35. [Accessed 22 March 2011]. Available from: http://www.censida.salud.gob.mx/ descargas/biblioteca/ProgAc2007-2012.pdf
44. World Health Organization. Guidance on provider-initiated HIV testing and counseling in health facilities. May 2007. [Accessed 22 March 2011]. Available from: http://www.who.int/mediacentre/news/releases/2007/pr24/en/index.html
45. McDonald AM, Li Y, Dore GJ, Ree H, Kaldor JM. Late HIV presentation among AIDS cases in Australia, 1992-2001. Aust NZ J Public Health 2003; (6): 608-613.
46. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4, 200cells/microL) with HIV infection. HIV Med 2004;5:93-98.
47. Sullivan AK, Curtis H, Sabin CA, Johnson MA. Newly diagnosed HIV infections: review in UK and Ireland. BMJ 2005:330(7503):1301-1302.
48. Delpierre C, Dray-Spíra R, Cuzin L, Marchou B, Massip P, Lang T, et al. VESPA Study Group. Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS 2007;18(5):312-317.
49. Brannstrom J, Akerlund B, Arneborn M, Blaxhult A, Giesecke J. Patients unaware of their HIV infection until AIDS diagnosis in Sweden 1996-2002. Int J STD AIDS 2005;16(10):702-706.
50. Donate AP, Rangel MG, Hovell MF, Santibáñez J, Sipan CL, Izazola JA. HIV infection in mobile populations: the case of Mexican migrants to the United States. Rev Panam Salud Publica 2005;17(1):26-29. PubMed PMID:15720878.
51. Essuon AD, Simmons DS, Stephens TT, Richter D, Lindley LL, Braithwaite RL Transient populations: linking HIV, migrant workers, and South African male inmates. J Health Care Poor Underserved 2009;20(Suppl 2):40-52. Review
52. Secretaria de Salud. Norma Oficial Mexicana NOM-010-SSA2-I993, para la prevención y control de la infección por virus de la inmunodeficiencia humana. México, 1993. [Accessed 22 March 2011]. Available from: http://www.salud.gob.mx/unidades/cdi/nom/010ssa23.html
53. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(RR-14):1-17; quiz CEI-4.
54. Donnell D, Kiarie J, Thomas K, Baeten J, Lingappa J, Cohen C, et al. ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant african couples: a multinational prospective study. 17th Conference on retroviruses and opportunistic infections (CROI 2010). San Francisco, USA. February 16-19, 2010. Abstract 136.
55. Bethesda, MD: National Institute of Allergy and Infectious Diseases. Treating HIV-infected people with antiretrovirals protects partners from infection: Findings result from NIH-funded international study [press release]; [Accessed: May 12, 2011]. Available from: http://www.niaid.nih. gov/news/newsreleases/201 l/Pages/HPTN052.aspx
56. Carrizosa CM, Blumberg EJ, Hovell MF, Martinez-Donate AP, Garcia-Gonzalez G, Lozada R, et al. Determinants and prevalence of late HIV testing in Tijuana, Mexico. AIDS Patient Care and STDs 2010;24(5):333-340.
57. Nogueda-Orozco MJ, Caro-Vega Y, Crabtree-Ramfrez B, Vázquez-Pineda F, Sierra-Madero J. Inicio tardío de tratamiento antirretroviral: ¡Qué factores psicosociales están involucrados? XXXVI Congreso Nacional de Infectología y Microbiología Clínica. Puebla, Junio 2011. Abstract H7.